Kyrgyzstan Medical Device Registration: Transition Period 2027-2028 and Compliance Action Plan

1. Key takeaways

The window for the Kyrgyzstan national route has been postponed, but it has not been canceled. On December 29, 2025, the Eurasian Economic Union member states signed a Protocol amending the years in Article 11 of the Agreement of December 23, 2014. In practice this comes down to three dates: applications for registration or expertise under the national route may be submitted until December 31, 2027; re-registration and registration dossier changes under the national route may be handled until December 31, 2028; and from January 1, 2028, new registrations are processed only under union rules. Reading this the wrong way around will cause the entire compliance program to be built backwards.

2. Legal basis

1. Agreement on Common Principles and Rules for the Circulation of Medical Devices (Medical Products and Medical Technology) within the Eurasian Economic Union, December 23, 2014, Article 11 (transition period provisions).
2. Protocol amending that Agreement, signed in Moscow on December 29, 2025: the deadline year for national-route applications is moved from 2025 to 2027, and the deadline year for re-registration and changes is moved from 2026 to 2028.
3. Entry into force mechanism of the Protocol: provisional application from the tenth day after signature; formal entry into force on the date the Eurasian Economic Commission receives the last written notification that a member state has completed its internal procedures.
4. Member state ratification progress verified so far: the House of Representatives of Belarus approved on June 3, 2026 (covering both the 2025-12-29 and 2026-02-09 Protocols); the Russian Federation approved by Federal Law No. 288-FZ of August 4, 2026.
5. Domestic ratification progress of the Kyrgyz Republic: no official original document was obtained in this verification round; the currently effective published text prevails.

3. Expert insights

Insight one: the Protocol changed only two years, but the two changes land differently.

The two sets of deadlines in the original Article 11 correspond to two different actions: submitting new applications and handling re-registration or dossier changes. The Protocol moves the first from 2025 to 2027 and the second from 2026 to 2028. A full one-year buffer is preserved between the two deadlines, and this is deliberate design: the final year closes off new applications, and the following year absorbs the stock of re-registrations and changes. Once this staggering is understood, it becomes clear why the year 2028 is especially critical.

Insight two: provisional application and formal entry into force are two different dates, and practice follows provisional application.

The Protocol applies provisionally from the tenth day after signature, while formal entry into force waits for every member state to complete internal procedures. The direct market implication is that from early January 2026, the national-route application channel has been operating on the new deadlines, and companies do not need to wait for all ratifications to finish. This is also why projects filing during 2026 are unaffected in terms of application acceptance.

Insight three: the real reason for the extension is that the union system is not yet ready to absorb the workload.

The reasoning given by the Minister of Health of Belarus when explaining the matter to parliament is representative: the member states agreed that the original deadlines were insufficient to complete the transition to union registration and to fully abandon national registration, and to avert the threat of device shortages in their markets the parties signed the Protocol extending the transition period. The extension is not a relaxation of requirements but an admission that the migration workload exceeds expectations, and companies should read this in reverse: queueing risk will concentrate in 2027 and 2028.

Insight four: ratification progress in Kyrgyzstan must be verified separately.

Member states are completing internal procedures at different speeds. Ratification milestones have been verified for Belarus and Russia, but no official original was obtained for the Kyrgyz Republic in this round. We recommend that project decisions rely on the currently effective text published by the Kyrgyz Republic, and that contracts and project plans retain flexibility for further deadline changes.

Insight five: the post-transition action list should be scheduled now.

The three dates map to three categories of action:

• Before 2027-12-31: submit applications for all new products intended to enter the market under the national route;
• From 2028-01-01: new registrations follow union rules only, so union-route scheduling must start early;
• Before 2028-12-31: complete re-registration and all known changes for existing products.

4. Practical recommendations

First, build a transition-period action ledger with three categories. Track new product applications, re-registration of existing products, and known changes as separate ledgers, each marked with its latest filing date and preparatory workload, and schedule backwards from those dates.

Second, treat 2027 as the launch year for the union route, not merely the closing year of the national route. The capacity of testing laboratories and expert organizations is limited. If all companies launch union-route work in the second half of 2027, queue times will stretch significantly. We recommend completing union-route technical preparation before the first half of 2027.

Third, preserve flexibility for further deadline changes. The transition period has already been postponed twice (2021 to 2025 to 2027). Commercial contracts and project plans should not hard-code the completion of migration by 2028 as an unadjustable constraint; a trigger-based clause is the better structure.

Fourth, run one concentrated cleanup of existing changes. Complete a full dossier review across the product portfolio during 2027 and submit all known change needs (model additions, site changes, authorized representative replacement, label updates) in a single batch, avoiding passive migration after 2029.

5. Verification checklist

• □ Verify the three key dates: 2027-12-31 (deadline for national-route applications), 2028-01-01 (new registrations under union rules only), 2028-12-31 (deadline for re-registration and changes);
• □ Confirm the start of provisional application of the Protocol: 10 days after 2025-12-29;
• □ Obtain the currently effective text published by the Kyrgyz Republic and check domestic ratification progress;
• □ Establish a transition-period action ledger (new applications, re-registration, known changes);
• □ Complete union-route technical preparation before the first half of 2027;
• □ Flexibility clauses for further deadline changes are included in commercial contracts and project plans.

Regulatory information verified as of October 29, 2026.

Our services cover: premarket pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance support, post-market surveillance and vigilance system setup, import and distribution compliance, fee estimation and project budget management.

GRZAN provides regulatory registration support in Kyrgyzstan for medical device manufacturers, importers and authorized representatives, covering the full pathway from route selection to post-market obligations.

The GRZAN regulatory team consists of professionals with years of hands-on experience in Eurasian Economic Union registrations and maintains a stable local collaboration network in Bishkek, Almaty, Tashkent, Moscow and other cities, working in Chinese, Russian and English. We deliver actionable solutions for the issues foreign manufacturers most often encounter in the CIS region, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection readiness.

We hold to one principle: every regulatory conclusion we publish must rest on verifiable official sources. Figures and timelines that cannot be verified are labeled as a practical estimate, and experience-based values are never presented as legal requirements.

For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services